Y-mAbs Therapeutics, Inc. financial data

Symbol
YMAB on Nasdaq
Industry
Pharmaceutical Preparations
Location
230 Park Avenue, Suite 3350, New York, New York
State of incorporation
Delaware
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2024 - Aug 12, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 448 % -1.83%
Quick Ratio 28.3 % +15.3%
Debt-to-equity 32.5 % +11.1%
Return On Equity -24.9 % +31.6%
Return On Assets -18.8 % +33.3%
Operating Margin -31.9 % +35.2%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 44.6M shares +2.18%
Common Stock, Shares, Outstanding 44.6M shares
Entity Public Float 246M USD -55.4%
Common Stock, Value, Issued 4K USD 0%
Weighted Average Number of Shares Outstanding, Basic 44M shares +0.82%
Weighted Average Number of Shares Outstanding, Diluted 44M shares +0.82%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 86.5M USD +1.84%
Research and Development Expense 54.4M USD -19.7%
Costs and Expenses 114M USD -10%
Operating Income (Loss) -27.6M USD +34%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -24M USD +38.3%
Income Tax Expense (Benefit) 642K USD +259%
Net Income (Loss) Attributable to Parent -24.6M USD +37%
Earnings Per Share, Basic -0.56 USD/shares +37.8%
Earnings Per Share, Diluted -0.56 USD/shares +37.8%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 77.8M USD -11.5%
Accounts Receivable, after Allowance for Credit Loss, Current 22.2M USD +16.1%
Inventory, Net 8.5M USD +63.8%
Other Assets, Current 2.24M USD -37.2%
Assets, Current 127M USD +9.48%
Property, Plant and Equipment, Net 87K USD -76.8%
Operating Lease, Right-of-Use Asset 1.27M USD +7.9%
Intangible Assets, Net (Excluding Goodwill) 2.45M USD -12.6%
Other Assets, Noncurrent 13.5M USD +9.88%
Assets 144M USD +8.79%
Accounts Payable, Current 10.2M USD +40.5%
Accrued Liabilities, Current 12.8M USD -20.8%
Liabilities, Current 43.5M USD +79.4%
Operating Lease, Liability, Noncurrent 432K USD +3.85%
Other Liabilities, Noncurrent 847K USD +3.8%
Liabilities 48.7M USD +75.7%
Accumulated Other Comprehensive Income (Loss), Net of Tax 1.05M USD +0.38%
Retained Earnings (Accumulated Deficit) -473M USD -5.49%
Stockholders' Equity Attributable to Parent 95.3M USD -8.93%
Liabilities and Equity 144M USD +8.79%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -3.48M USD +73.5%
Net Cash Provided by (Used in) Financing Activities 588K USD
Common Stock, Shares Authorized 100M shares 0%
Common Stock, Shares, Issued 44.6M shares +2.17%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -2.89M USD +78%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 77.8M USD -11.5%
Deferred Tax Assets, Valuation Allowance 149M USD +4.49%
Operating Lease, Liability 1.27M USD +2.33%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -24.6M USD +40.2%
Lessee, Operating Lease, Liability, to be Paid 1.38M USD -0.15%
Operating Lease, Liability, Current 842K USD +1.57%
Lessee, Operating Lease, Liability, to be Paid, Year Two 187K USD -49.3%
Lessee, Operating Lease, Liability, to be Paid, Year One 681K USD +42.8%
Operating Lease, Weighted Average Discount Rate, Percent 0.09 pure 0%
Deferred Income Tax Expense (Benefit) 0 USD
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 101K USD -23.5%
Lessee, Operating Lease, Liability, to be Paid, Year Three 16K USD
Deferred Tax Assets, Operating Loss Carryforwards 83.2M USD -3.29%
Preferred Stock, Shares Issued 0 shares
Current Income Tax Expense (Benefit) 100K USD -44.1%
Preferred Stock, Shares Authorized 5.5M shares 0%
Unrecognized Tax Benefits 0 USD
Operating Lease, Payments 1.03M USD -35.9%
Additional Paid in Capital 568M USD +2.76%
Depreciation, Depletion and Amortization 159K USD -12.6%
Share-based Payment Arrangement, Expense 3.44M USD -4.9%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%